Topic 1 Pharmacogenetics of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism 1. Is the pharmacokinetic and clinical evidence presented sufficient to demonstrate that homozygous UGT1A1*28 genotypes (7 7 ge - prodrugs - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2004-10-14 14:44:52 Clinical trials Epidemiology Medical research Medical terms Prodrugs Biomarker Irinotecan Surrogate endpoint CYP3A4 Medicine Chemistry Health		Topic 1 Pharmacogenetics of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism 1. Is the pharmacokinetic and clinical evidence presented sufficient to demonstrate that homozygous UGT1A1*28 genotypes (7/7 ge Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 33,00 KB Share Document on Facebook

	PDF Document DocID: 1w1FC - View Document
	PROUD PROUD Participant Involvement meeting: Trial Design Date: Tuesday 9th September – 20.00 Venue: MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, Holborn, WC2B 6NH Contact person: Mitzy Gaf DocID: 1vq4y - View Document
	Flex Databases Modules Overview Flex Databases is a company providing e-solutions for clinical trials. Software provided by Flex Databases helps making the processes of conducting clinical trials and managing pharma, bio DocID: 1vpVH - View Document
	Flex Databases Modules Overview Flex Databases is a company that provides e-solutions for clinical trials. Software provided by Flex Databases makes the entire clinical trials process and the management of pharma, biotec DocID: 1vjk6 - View Document
	Facilities and Resources Clinical Trials Office Lawrence Flaherty, M.D., Medical Director Lisa Lange, ANP-BC, VP, Clinical Trials Office http://www.karmanos.org/cto DocID: 1vg8R - View Document